These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33177346)

  • 41. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
    Liu R; Staller K
    Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of Mesalamine in Irritable Bowel Syndrome.
    Dai C; Jiang M; Huang YH
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3462-3463. PubMed ID: 37001712
    [No Abstract]   [Full Text] [Related]  

  • 43. Modern Management of Irritable Bowel Syndrome: More Than Motility.
    Tack J; Vanuytsel T; Corsetti M
    Dig Dis; 2016; 34(5):566-73. PubMed ID: 27331917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
    Chen M; Tang TC; Wang Y; Shui J; Xiao XH; Lan X; Yu P; Zhang C; Wang SH; Yao J; Zheng H; Huang DQ
    Aliment Pharmacol Ther; 2018 Jul; 48(2):160-168. PubMed ID: 29856472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
    Maxton DG; Morris J; Whorwell PJ
    Aliment Pharmacol Ther; 1996 Aug; 10(4):595-9. PubMed ID: 8853764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of Peppermint oil in diarrhea predominant IBS - a double blind randomized placebo - controlled study.
    Alam MS; Roy PK; Miah AR; Mollick SH; Khan MR; Mahmud MC; Khatun S
    Mymensingh Med J; 2013 Jan; 22(1):27-30. PubMed ID: 23416804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Practical Evaluation and Management of Irritable Bowel Syndrome with Diarrhea: A Case Study Approach.
    Lacy BE
    J Fam Pract; 2018 Aug; 67(8 suppl):S31-S36. PubMed ID: 30137051
    [No Abstract]   [Full Text] [Related]  

  • 50. Reply to Black and Ford.
    Plasse TF
    Am J Gastroenterol; 2021 Feb; 116(2):429. PubMed ID: 33110016
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
    Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
    Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR
    Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of irritable bowel syndrome].
    Németh AM
    Orv Hetil; 2004 Jul; 145(30):1573-5. PubMed ID: 15382621
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and indication optimization of Chinese medicine (Tiao-Chang Ke-Min granules) for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial.
    Li Q; Zhang BP; Huang SG; Ouyang WW; Xie JH; Wen ZH; Yang XB
    Trials; 2018 Jul; 19(1):367. PubMed ID: 29996882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
    Hirata T; Funatsu T; Keto Y; Akuzawa S; Akiho H; Nishida A; Sasamata M; Miyata K
    Nihon Yakurigaku Zasshi; 2009 May; 133(5):281-91. PubMed ID: 19443966
    [No Abstract]   [Full Text] [Related]  

  • 57. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
    Lembo AJ; Lacy BE; Zuckerman MJ; Schey R; Dove LS; Andrae DA; Davenport JM; McIntyre G; Lopez R; Turner L; Covington PS
    N Engl J Med; 2016 Jan; 374(3):242-53. PubMed ID: 26789872
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of the effect of sachet formulation of almond (Amygdalus dulcis L.) on diarrhea prominent irritable bowel syndrome (IBS-D) symptoms: A clinical trial.
    Darvishmoghadam S; Ansari M; Ahmadipour H; Azimipour M; Esmaeilzade M; Zahedi MJ; Hayat Bakhsh Abbasi M; Ahmadi B; Asadi A; Sharififar F
    Complement Ther Med; 2019 Aug; 45():242-247. PubMed ID: 31331568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea].
    Iakovenko EP; Agafonova NA; Pokhal'skaia OIu; Kolganova AV; Nazarbekova RS; Ivanov AN; Davletshina IV; Popova EV; Prianishnikova AS; Ovchinnikova NI; Iakovenko AV; Aldiiarova MA; D'iachkoava AV; Gioeva IZ
    Klin Med (Mosk); 2008; 86(10):47-52. PubMed ID: 19069460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
    Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.